研發與技術
R&D and Technology
Rational Development of a Polysaccharide-Protein-Conjugated Nanoparticle Vaccine Against SARS-CoV-2 Variants and Streptococcus pneumoniae
2022-08-30
999+
學術論著
上一篇：Efficacy Safety and Pharmacokinetics of Recombinant Human Coagulation Factor VIII (Omfiloctocog alfa) in Previously Treated Children with Severe Hemophilia A.
下一篇：Immunogenicity correlation in cynomolgus monkeys between Luminex‐d total IgG immunoassay and pseudovirion‐ d neutralization assay for a 14‐valent recombinant human papillomavirus vaccine
最新資訊
-
2024-SCT-I10A combined with a bevacizumab biosimilar (SCT510) versus sorafenib in the first-line treatment of advanced hepatocellular carcinoma A randomized phase 3 trial
2024-06-20 -
2024-Rapid development and mass production of SARS-CoV-2 neutralizing chicken egg yolk antibodies with protective efficacy in hamsters
2024-05-06 -
2024-Immunogenicity of Tetravalent Protein Vaccine against SARS-CoV-2 EG.5 Subvaraint A Phase 2 Trial
2024-02-08 -
2024-Finotonlimab with chemotherapy in recurrent or static head and neck cancer a randomized phase 3 trial
2024-06-02